Life Semantics

About Life Semantics

Life Semantics, a South Korean digital healthcare company, was established in 2012 by Song Seung-jae. The company has positioned itself at the intersection of medical information technology and artificial intelligence, focusing on creating a digital health ecosystem. A significant milestone was its IPO on the KOSDAQ market in March 2021, becoming the first digital therapeutics developer in Korea to do so. The initial public offering aimed to fund the advancement of its product technology and global market expansion. However, in 2024, it was announced that founder Song Seung-jae would be stepping down as CEO and selling the majority of his shares, with aerospace materials company Spear Korea set to become the largest shareholder. Spear Korea intends to continue Life Semantics' existing digital health operations while also exploring applications in the aerospace medicine sector.

The core of Life Semantics' business is its proprietary technology platform, 'LifeRecord'. This platform integrates scattered personal health records (PHR) from hospitals and corporations to enable personalized health management solutions. LifeRecord is designed for high security, having obtained both ISMS-P (Personal Information and Information Security Management System) and HIPAA (Health Insurance Portability and Accountability Act) certifications. The company's business model is diversified, generating revenue through B2B and B2C channels. It provides its platform to enterprises like insurance and healthcare companies for their own digital service development and also offers direct-to-consumer services. The business has expanded to include a health functional food subsidiary, NutraSemantics, and a data-based insurance and healthcare product sales company, Nexus Bridge.

Life Semantics has developed a portfolio of solutions built upon its LifeRecord platform. A key offering is 'Dr. Call,' a non-face-to-face telemedicine platform that facilitates video consultations, online second opinions, and prescription transmissions between patients and medical professionals. Initially launched for overseas Koreans through a regulatory sandbox, its service scope later expanded to domestic users. In the realm of digital therapeutics (DTx), the company has branded its solutions as 'Redpill', with pipelines including 'Redpill Breath' for respiratory rehabilitation and 'Redpill Care' for cancer patient prognosis management. Additionally, the company has developed AI-driven diagnostic tools, such as 'canopyMD HDAI,' an AI for analyzing hair density, and is working on solutions for predicting diseases like prostate cancer.